Korean J Thorac Cardiovasc Surg.  2020 Dec;53(6):368-374. 10.5090/kjtcs.20.023.

Outcome of Extracorporeal Ventricular Assist Device for Cardiogenic Shock as a Bridge to Transplantation

• Kim HH
• Shin JH
• Kim JH
• Youn YN

• KMID: 2509408
• DOI: http://doi.org/10.5090/kjtcs.20.023

Abstract

Background
The extracorporeal ventricular assist device (e-VAD) system is designed for left ventricular support using a permanent life support console. This study aimed to determine the impact of temporary e-VAD implantation bridging on posttransplant outcomes.
Methods
We reviewed the clinical records of 6 patients with the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile 1, awaiting heart transplantation, who were provided with temporary e-VAD from 2018 to 2019. The circuit comprised a single centrifugal pump without an oxygenator. The e-VAD inflow cannula was inserted into the apex of the left ventricle, and the outflow cannula was positioned in the ascending aorta. The median follow-up duration was 8.4±6.9 months.
Results
After e-VAD implantation, lactate dehydrogenase levels significantly decreased, and Sequential Organ Failure Assessment scores significantly improved. Bedside rehabilitation was possible in 5 patients. After a mean e-VAD support duration of 14.5±17.3 days, all patients were successfully bridged to transplantation. After transplantation, 5 patients survived for at least 6 months.
Conclusion
e-VAD may reverse end-organ dysfunction and improve outcomes in INTERMACS I heart transplant patients.

Keyword

Heart-assist devices; Heart transplantation; Heart transplantation